KR20230044355A - 미로가발린베실산염을 함유하는 구강내 붕괴정 - Google Patents

미로가발린베실산염을 함유하는 구강내 붕괴정 Download PDF

Info

Publication number
KR20230044355A
KR20230044355A KR1020227039166A KR20227039166A KR20230044355A KR 20230044355 A KR20230044355 A KR 20230044355A KR 1020227039166 A KR1020227039166 A KR 1020227039166A KR 20227039166 A KR20227039166 A KR 20227039166A KR 20230044355 A KR20230044355 A KR 20230044355A
Authority
KR
South Korea
Prior art keywords
orally disintegrating
disintegrating tablet
weight
mirogabalin
besylate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227039166A
Other languages
English (en)
Korean (ko)
Inventor
신지 요시나가
도시유키 나카하시
Original Assignee
다이이찌 산쿄 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다이이찌 산쿄 가부시키가이샤 filed Critical 다이이찌 산쿄 가부시키가이샤
Publication of KR20230044355A publication Critical patent/KR20230044355A/ko
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020227039166A 2020-07-27 2021-07-26 미로가발린베실산염을 함유하는 구강내 붕괴정 Pending KR20230044355A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2020-126311 2020-07-27
JP2020126311 2020-07-27
PCT/JP2021/027505 WO2022024979A1 (ja) 2020-07-27 2021-07-26 ミロガバリンベシル酸塩を含有する口腔内崩壊錠

Publications (1)

Publication Number Publication Date
KR20230044355A true KR20230044355A (ko) 2023-04-04

Family

ID=80036359

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227039166A Pending KR20230044355A (ko) 2020-07-27 2021-07-26 미로가발린베실산염을 함유하는 구강내 붕괴정

Country Status (6)

Country Link
JP (1) JP7744908B2 (https=)
KR (1) KR20230044355A (https=)
CN (1) CN115803020A (https=)
BR (1) BR112023000403A2 (https=)
TW (1) TWI883230B (https=)
WO (1) WO2022024979A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2024248079A1 (https=) * 2023-06-02 2024-12-05
CN116966158B (zh) * 2023-08-14 2025-10-21 四川制药制剂有限公司 一种富马酸丙酚替诺福韦片的制备方法
CN118948808B (zh) * 2024-08-07 2025-11-25 山东大学 一种苯磺酸米洛巴林口溶膜剂及其制备方法
CN120437109B (zh) * 2025-07-09 2025-09-26 湖南一格制药有限公司 一种稳定性优异的苯磺酸美洛加巴林制剂组合物
CN121221543A (zh) * 2025-11-26 2025-12-30 华润双鹤利民药业(济南)有限公司 一种苯磺酸美洛加巴林口崩片制剂及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150079166A1 (en) 2013-04-04 2015-03-19 Daiichi Sankyo Company, Limited Solid Compositions Comprising a Salt of Aminocarboxylic Acid
US20150110880A1 (en) 2012-04-24 2015-04-23 Daiichi Sankyo Company, Limited Orally disintegrating tablet and production process therefor
US20180042878A1 (en) 2015-03-19 2018-02-15 Daiichi Sankyo Company, Limited Solid preparation including antioxidant
US20180243223A1 (en) 2015-03-19 2018-08-30 Daiichi Sankyo Company, Limited Solid preparation including colorant

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003034655A (ja) * 2001-05-15 2003-02-07 Takeda Chem Ind Ltd 速崩壊性固形製剤
US7390503B1 (en) * 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
US8486450B2 (en) * 2005-12-28 2013-07-16 Takeda Pharmaceutical Company Limited Method of producing solid preparation disintegrating in the oral cavity
JP5295506B2 (ja) * 2006-02-21 2013-09-18 第一三共株式会社 レボフロキサシン含有錠剤
ES2393640T3 (es) * 2008-02-13 2012-12-26 Dainippon Sumitomo Pharma Co., Ltd. Comprimidos bucodisgregables
JP5308042B2 (ja) * 2008-03-11 2013-10-09 新田ゼラチン株式会社 マンゴー抽出物
JP5031054B2 (ja) * 2010-03-18 2012-09-19 信越化学工業株式会社 低置換度ヒドロキシプロピルセルロース及びこれを含む固形製剤
TWI812602B (zh) * 2016-12-01 2023-08-21 日商第一三共股份有限公司 含二胺衍生物之口腔崩散錠及其製造方法
JP7182356B2 (ja) * 2017-07-05 2022-12-02 日本ケミファ株式会社 口腔内崩壊錠及びその製造方法
JPWO2019021957A1 (ja) * 2017-07-25 2020-07-09 第一三共株式会社 点鼻用乾燥粉末医薬組成物
JP7148319B2 (ja) * 2017-08-17 2022-10-05 第一三共株式会社 プラスグレルを含む口腔内崩壊錠
BR112021001008A2 (pt) * 2018-07-30 2021-04-20 Daiichi Sankyo Company, Limited comprimido de fármaco
CN110742868A (zh) * 2019-11-20 2020-02-04 合肥拓锐生物科技有限公司 一种Mirogabalin Besilate口腔崩解片

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150110880A1 (en) 2012-04-24 2015-04-23 Daiichi Sankyo Company, Limited Orally disintegrating tablet and production process therefor
US20150079166A1 (en) 2013-04-04 2015-03-19 Daiichi Sankyo Company, Limited Solid Compositions Comprising a Salt of Aminocarboxylic Acid
US20180042878A1 (en) 2015-03-19 2018-02-15 Daiichi Sankyo Company, Limited Solid preparation including antioxidant
US20180243223A1 (en) 2015-03-19 2018-08-30 Daiichi Sankyo Company, Limited Solid preparation including colorant

Also Published As

Publication number Publication date
JPWO2022024979A1 (https=) 2022-02-03
TWI883230B (zh) 2025-05-11
JP7744908B2 (ja) 2025-09-26
WO2022024979A1 (ja) 2022-02-03
BR112023000403A2 (pt) 2023-02-07
CN115803020A (zh) 2023-03-14
TW202220643A (zh) 2022-06-01

Similar Documents

Publication Publication Date Title
TWI572371B (zh) 口腔內崩壞錠及其製造方法
JP7744908B2 (ja) ミロガバリンベシル酸塩を含有する口腔内崩壊錠
JP7096164B2 (ja) ジアミン誘導体を含む口腔内崩壊錠
JP2025108517A (ja) ピロールカルボキサミドを含む口腔内崩壊錠
ES2985625T3 (es) Formas de dosificación sólidas de vigabatrina
TW201618770A (zh) 經遮蔽具苦味藥劑的苦味之經口投與製劑
JP7148319B2 (ja) プラスグレルを含む口腔内崩壊錠
JP5275815B2 (ja) リスペリドンを含有する口腔内崩壊錠剤および苦味抑制製剤
JP7133811B2 (ja) 錠剤
JP6538321B2 (ja) 経口組成物
JP2022072050A (ja) エドキサバンを含有する口腔内崩壊錠
HK40082826A (en) Orally disintegrating tablet containing mirogabalin besilate
TW201532634A (zh) 固形製劑
JP2016117652A (ja) 小児への投与に適した速崩壊錠とその簡便な製造方法
JP2018199674A (ja) 認知症治療薬を含有する口腔内崩壊性錠剤
JP6150564B2 (ja) 口腔内速崩壊性錠剤
GB2644236A (en) Orodispersible tablet composition containing carbidopa and levodopa
JP6853828B2 (ja) メマンチンまたはその薬学上許容される塩を含有する医薬組成物
DK177906B1 (en) Dispersible tablet

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902